Get the Stockscreener App
4.26
5.12%
-0.23
After Hours:
4.38
0.12
+2.82%
Nrx Pharmaceuticals Inc stock is traded at $4.26, with a volume of 719.39K.
It is down -5.12% in the last 24 hours and up +255.00% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$4.49
Open:
$4.31
24h Volume:
719.39K
Relative Volume:
0.74
Market Cap:
$51.52M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-1.065
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
+13.30%
1M Performance:
+255.00%
6M Performance:
+70.40%
1Y Performance:
+0.09%
1-Day Range:
$4.05
$4.48
1-Week Range:
$3.72
$6.01
52-Week Range:
$1.10
$7.333
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
4.26 | 51.52M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.96 | 107.38B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.23 | 76.18B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
659.81 | 39.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
249.16 | 32.14B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.76 | 27.03B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRx Pharmaceuticals Strengthens Board with Key Financial and Healthcare Veterans After $27M Deal - StockTitan
NRx Pharmaceuticals Board Member Resigns, New Member to be Appointed - Defense World
NRx Pharmaceuticals director resigns, new nominee expected By Investing.com - Investing.com South Africa
NRx Pharmaceuticals director resigns, new nominee expected - Investing.com
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel - StreetInsider.com
NRx Pharmaceuticals' Future CMO Featured on CNN Special About Ketamine Therapy - StockTitan
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market - Quantisnow
NRx Pharmaceuticals Pursues NASDAQ Global Market Uplisting to Boost Institutional Access - StockTitan
NRx Pharmaceuticals, Inc. announced that it expects to receive $2.0002 million in funding - Marketscreener.com
NRx Pharmaceuticals Announces Entry into Share Purchase Agreement with HOPE Therapeutics and JGS Holdings LLC - Defense World
NRXPNRX Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
NRx Pharmaceuticals Secures $25M Backing for Massive Mental Health Clinic Expansion - StockTitan
D. Boral Capital Reaffirms “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - Defense World
Best Momentum Stocks to Buy for January 6th - MSN
Agreement for $27 Million in Funding for Expanding Clinic Acquisitions and Operations, Plus New Drug Application for Treatment of Suicidal Depression: NRx Pharmaceuticals, Inc. Stock Symbol: NRXP - Barchart
Stock market news: Hoth Therapeutics +184.32%, DatChat +79.85% among top gainers during mid day trading - Business Upturn
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventiona - StreetInsider.com
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTS - PR Newswire
Agreement for $27 Million in Funding for Expanding Clinic - openPR
NRx stock rallies 35% on equity purchases, clinic acquisition - MSN
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:N - GuruFocus.com
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations - PR Newswire
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics - PR Newswire
NRx Pharmaceuticals (NASDAQ:NRXP) and Lexaria Bioscience (NASDAQ:LEXX) Head to Head Contrast - Defense World
HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025 - PR Newswire
NRx Pharmaceuticals (NRXP) Rises Before An Investor Workshop - Stocks Telegraph
HOPE Therapeutics Plans $100M Revenue Mental Health Clinic Acquisition Strategy at Mar-a-Lago Workshop - StockTitan
Acquisition of Kadima Neuropsychiatry Institute for CNS & - openPR
Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics - The Malaysian Reserve
NRx Pharma unit to acquire psychiatric facility Kadima - MSN
NRx Pharmaceuticals Stock Rises 33% on Psychiatry Clinic Acquisition - MarketWatch
NRx Pharmaceuticals Announces Agreement with LifeSci Associates to Provide Financial Services and Support - GuruFocus.com
NRx Pharma to buy Kadima psychiatric clinic (NRXP:NASDAQ) - Seeking Alpha
NRx Pharmaceuticals (NASDAQ:NRXP) Earns Buy Rating from D. Boral Capital - Defense World
NRx Pharmaceuticals (NASDAQ:NRXP) Given “Buy” Rating at D. Boral Capital - Defense World
Walt Disney Company (DIS-N) QuotePress Release - The Globe and Mail
Crowdstrike Holdings Inc (CRWD-Q) QuotePress Release - The Globe and Mail
New Drug Application to the FDA for the Treatment of Suicidal - openPR
NRx Pharmaceuticals Takes Bold Step Toward FDA Approval for NRX-100 in Treatment of Suicidal Depression - Tandav Media
Best Momentum Stocks to Buy for December 30th - Yahoo Finance
NRx Pharmaceuticals seeks FDA nod for suicidal depression drug - Investing.com India
NRx Pharmaceuticals seeks FDA nod for suicidal depression drug By Investing.com - Investing.com Nigeria
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression - StreetInsider.com
New Strong Buy Stocks for December 24th - MSN
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024 - The Eastern Progress Online
NRX Pharmaceuticals chairman Jonathan Javitt buys $46,800 in stock By Investing.com - Investing.com Canada
NRX Pharmaceuticals chairman Jonathan Javitt buys $46,800 in stock - Investing.com India
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic - Kilgore News Herald
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics - The Eastern Progress Online
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024 - The Eastern Progress Online
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.89%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):